e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Symptoms, risks, complications and palliative care in thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
R. Gijtenbeek (Leeuwarden, Netherlands), G. Helfrich (Rotterdam, Netherlands), B. Venmans (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), W. Van Geffen (Leeuwarden, Netherlands)
Source:
International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Session:
Symptoms, risks, complications and palliative care in thoracic oncology
Session type:
Thematic Poster
Number:
4658
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Gijtenbeek (Leeuwarden, Netherlands), G. Helfrich (Rotterdam, Netherlands), B. Venmans (Leeuwarden, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), K. De Jong (Leeuwarden, Netherlands), W. Van Geffen (Leeuwarden, Netherlands). Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC). 4658
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
The treatment of stage IV non-small cell lung cancer with target therapies
Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC?
Year: 2013
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
FEV
1
is not a prognostic marker in operated patients with stage I or II non-small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Surgery for lung cancer: pre-operative evaluation and results
Year: 2011
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007
Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)?
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S)
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002
Treatment of early (stage I/II) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept